Hit enter to search or ESC to close
Oblato
  • About Oblato
    • Who We Are
    • History of Progress
  • Our Science
    • Core Technology
    • Presentations
    • Publications
  • Pipeline
    • OKN-007
  • Clinical Development
    • Clinical Trials
    • Expanded Access Program (EAP)
  • Patients
    • Glioblastoma Multiforme (GBM)
    • Diffuse Intrinsic Pontine Glioma (DIPG)
  • News & Media
  • Contact Us
All Posts By

specialog

News

Oblato Announces Fast Track Designation of OKN-007 for Diffuse Intrinsic Pontine Glioma from the FDA

News

Oblato Announces Discussion Outcome with FDA for Development of OKN-007 for Diffuse Intrinsic Pontine Glioma

News

Brain cancer survivor marks Thanksgiving milestone

News

Brain tumor drug receives rare disease designations from the FDA

Recent Posts

  • Oblato announces that it has completed enrollment of patients for the Phase 2 recurrent glioblastoma multiforme clinical trial in the US
  • Oblato Announces that it has received a Positive Response from the FDA for the use of OKN-007 for patients with high-grade gliomas in an Expanded Access Program
  • Oblato Announces Fast Track Designation of OKN-007 for Diffuse Intrinsic Pontine Glioma from the FDA
  • Oblato Announces Discussion Outcome with FDA for Development of OKN-007 for Diffuse Intrinsic Pontine Glioma
  • Brain cancer survivor marks Thanksgiving milestone

Recent Comments

    ⓒ Oblato, Inc., 2021. All Rights Reserved.

    • About Oblato
      • Who We Are
      • History of Progress
    • Our Science
      • Core Technology
      • Presentations
      • Publications
    • Pipeline
      • OKN-007
    • Clinical Development
      • Clinical Trials
      • Expanded Access Program (EAP)
    • Patients
      • Glioblastoma Multiforme (GBM)
      • Diffuse Intrinsic Pontine Glioma (DIPG)
    • News & Media
    • Contact Us